Fluvoxamine, an antidepressant, is one of four FDA-approved repurposed medications tested in ACTIV-6, a nationwide remote study.

Speaking to media in a virtual briefing, infectious disease specialist Dr. Cameron Wolfe and David Montefiori, Ph.D., director of the Duke Human Vaccine Institute, said booster shots continue to be effective for those Americans who routinely get them.

The Duke Clinical and Translational Science Institute (CTSI) is collaborating with the Duke Department of Emergency Medicine on a study to evaluate the effectiveness of COVID-19 vaccines and the long-term impact of infection among health care personnel.

Surveillance testing, as well as other aspects of COVID-19 response, come to an end on Duke's campus.

Cancer patients said the COVID-19 pandemic heightened infection concerns, increased feelings of fear, and disrupted their care, according to a research questionnaire.

Production will enable human studies to determine whether the vaccine protects against a wide variety of coronaviruses, including those that cause COVID-19 

As chief operating officer at the Duke Human Vaccine Institute (DHVI), Thomas Denny is in the unique position of helping people fight flu and HIV, developing the next generation of COVID-19 vaccines, and all the while leading an annual $120 million enterprise.

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between participants taking ivermectin and participants taking a placebo.

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the antidepressant fluvoxamine 50 mg twice daily for 10 days for the treatment of mild-to-moderate COVID-19 symptoms.

Dr. Susanna Naggie and her colleagues at Duke University School of Medicine knew that COVID-19 was disproportionately impacting communities of color through higher rates of infection, severity of disease and associated adverse outcomes. Determined to be part of the solution, they set out to understand and address these disparities in real time.